Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.82 USD
Change Today -0.44 / -5.33%
Volume 37.7K
NRX On Other Exchanges
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

nephrogenex inc (NRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/31/14 - $17.98
52 Week Low
08/25/14 - $3.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEPHROGENEX INC (NRX)

Related News

No related news articles were found.

nephrogenex inc (NRX) Related Businessweek News

No Related Businessweek News Found

nephrogenex inc (NRX) Details

NephroGenex, Inc., a drug development company, focuses on developing novel therapies for kidney disease. It develops Pyridorin (pyridoxamine dihydrochoride), a therapeutic agent, which is in Phase III clinical study for the treatment of diabetic nephropathy. The company also engages in studying the application of an intravenous formulation of Pyridorin to specific types of acute kidney injury in patients where pathogenic oxidative chemistries have been identified as a contributing factor to the severity of this condition. NephroGenex, Inc. was founded in 2004 and is headquartered in Raleigh, North Carolina.

11 Employees
Last Reported Date: 03/24/15
Founded in 2004

nephrogenex inc (NRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $804.1K
President and Chief Scientific Officer
Total Annual Compensation: $499.7K
Chief Financial Officer, Secretary and Treasu...
Total Annual Compensation: $432.0K
Vice President of Product Development & Regul...
Total Annual Compensation: $298.8K
Compensation as of Fiscal Year 2014.

nephrogenex inc (NRX) Key Developments

NephroGenex, Inc. Announces Positive Results on Preclinical Studies that Evaluate Pyridorin as a Treatment for Acute Kidney Injury

NephroGenex, Inc. announced positive results on preclinical studies that evaluate Pyridorin as a treatment for acute kidney injury. The data are being presented at the National Kidney Foundation’s 2015 Spring Clinical Meetings. Pyridorin is a novel compound shown to target and reduce pathogenic oxidative chemistries that emerge in kidney disease. Oral Pyridorin is being evaluated in a pivotal Phase 3 program in diabetic nephropathy. In the poster session, “Pyridorin Treatment in Ischemia-Reperfusion Model of AKI,” researchers reported on a preclinical model of hospital-acquired acute kidney injury (AKI), a major cause of morbidity, extended hospitalizations and increased medical costs. AKI can occur from a decreased renal reperfusion during surgery, contrast-dye infusion, and anti-cancer therapies. The AKI that results from these procedures is accompanied by an increase in pathogenic oxidative chemistries which likely contributes to the kidney tissue damage and reduced renal function that develops in this indication. Pyridorin scavenges and inhibits pathogenic oxidative chemistries, and therefore could be a promising treatment for AKI. The study showed that treatment with Pyridorin significantly reduced the severity of acute kidney injury in a model of ischemia reperfusion, which emulates the AKI that can result following cardiopulmonary bypass surgery. Mice were administered doses of Pyridorin prior to the surgically-induced AKI. Pyridorin treatment was shown to significantly reduce the level of kidney injury, enhance renal function recovery, and reduce post-injury fibrosis. Treatment with a higher dose of Pyridorin was shown to be even more beneficial. Also at the meeting, the Company presented PIONEER, the ongoing pivotal Phase 3 trial with Pyridorin in diabetic nephropathy. In a poster session, “Design of a Phase 3 Clinical Trial in Type 2 Diabetic Nephropathy with Pyridoxamine dihydrochloride (Pyridorin),” lessons from previous studies in diabetic nephropathy were discussed, along with the use of a novel renal endpoint that is being used as the primary approvable endpoint. A Special Protocol Assessment (SPA) has been granted to this program by the U.S. FDA.

NephroGenex, Inc. Announces Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

NephroGenex, Inc. announced earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $5,233,000 against $1,049,000 a year ago. Net loss was $5,282,000 against $4,154,000 a year ago. Net loss per share - basic and diluted was $0.60 against $12.99 a year ago. For the year, the company reported loss from operations of $16,587,000 against $2,506,000 a year ago. Net loss was $16,820,000 against $6,305,000 a year ago. Net loss per share - basic and diluted was $2.15 against $19.71 a year ago.

NephroGenex, Inc. to Report Q4, 2014 Results on Mar 24, 2015

NephroGenex, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 24, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRX:US $7.82 USD -0.44

NRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation NRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPHROGENEX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at